Accéder au contenu
Merck
Toutes les photos(1)

Documents

1359415

USP

Levetiracetam Racemic Mixture

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(RS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(RS)-(2-Oxopyrrolidin-1-yl)butyramide, Etiracetam

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C8H14N2O2
Numéro CAS:
33996-58-6
Poids moléculaire :
170.21
Numéro Beilstein :
1529106
Numéro MDL:
MFCD00868507
Code UNSPSC :
41116107
ID de substance PubChem :
329750034
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

levetiracetam

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCC(N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)

Clé InChI

HPHUVLMMVZITSG-UHFFFAOYSA-N

Description générale

Levetiracetam racemic mixture also know as etiracetam is an stuctural analogue ethylated piracetam drug.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam Racemic Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Levetiracetam

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1359404

Levetiracetam, United States Pharmacopeia (USP) Reference Standard

1359437

(S)-(+)-2-Aminobutanmide hydrochloride, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001256

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001257

Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

PHR1447

Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001962

(R)-(+)-α-Methylbenzylamine, European Pharmacopoeia (EP) Reference Standard

Y0001948

(S)-(+)-2-Aminobutanmide hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR2432

(S)-(+)-2-Aminobutanmide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Exclamation markEnvironment
GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H319,H411

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Aaron M Cook et al.
Neurocritical care, 19(2), 210-214 (2013-08-03)
Increased creatinine clearance and subsequent elevated antimicrobial clearance is evident in many traumatic brain injury (TBI) patients due to augmented renal clearance (ARC). Little is known about the effects of ARC on other renally-eliminated medications, such as the anti-epileptic drug
Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study.
Rocco Salvatore Calabrò et al.
Epilepsy & behavior : E&B, 29(1), 254-255 (2013-08-14)
Radica M Stepanovic-Petrovic et al.
Anesthesiology, 120(3), 737-750 (2013-09-28)
The β-lactam antibiotic ceftriaxone stimulates glutamate transporter GLT-1 expression and is effective in neuropathic and visceral pain models. This study examined the effects of ceftriaxone and its interactions with different analgesics (ibuprofen, celecoxib, paracetamol, and levetiracetam) in somatic and visceral
Yahya Guvenc et al.
Turkish neurosurgery, 23(5), 617-622 (2013-10-09)
This study aimed to investigate the effects of a new generation antiepileptic agent, levetiracetam, on the neural tube development in a chick embryo model that corresponds to the first month of vertebral development in mammals. Forty-five Atabey® breed fertilized chicken
Young Jin Lee et al.
CNS drugs, 27(9), 753-759 (2013-08-08)
Antiepileptic drugs are commonly given for perioperative prophylaxis after brain tumor surgery, and there has been growing interest in levetiracetam, a second-generation antiepileptic drug. This retrospective study compared the seizure outcomes, side effects and durability of levetiracetam with valproic acid
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique